Non-recurrent laryngeal nerve with dual branch pattern and merging: a rare anatomical variant encountered during right hemithyroidectomy.

Surg Radiol AnatOct 26, 2026 (epub)

Badriya Yussuf, Haissan Iftikhar

✦ AI-curated · Sources linked

Case in brief

A woman in her 50s underwent right hemithyroidectomy for a benign compressive multinodular goitre. The recurrent laryngeal nerve was not found in its expected tracheo-oesophageal groove position. Tracing the vagus nerve revealed a right non-recurrent laryngeal nerve that divided into superior and inferior branches, which followed separate courses before rejoining about 10 mm from laryngeal entry. Both branches were identified and preserved. She had normal vocal cord function after extubation and an uncomplicated recovery without voice change at follow-up.

What made this case unusual

The non-recurrent nerve divided into two branches that re-merged before entering the larynx, adding complexity to identification and preservation.

Diagnostic / clinical pearl

When a recurrent laryngeal nerve is absent from its expected course, trace the vagus; follow all identified nerve branches fully, as a non-recurrent nerve may divide and re-merge.

Source

Published in Surg Radiol Anat. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in General Surgery

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.